NCT05399992Active, not recruiting
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
VICTORION REAL: An International Prospective Real-world Study to Evaluate the LDL-C changE and Adherence to incLisiran in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 847 (actual)
- First submitted
- 27 May 2022
- Start date
- 12 Sept 2022
- Primary completion date
- 5 Oct 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT05399992
What you commit to
- Study type: Observational
- Participants enrolled: 847
- From 12 Sept 2022 to the primary completion date, 5 Oct 2026
- 34 sites in 8 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants that have received inclisiran previously
- Participants participating in a clinical trial with investigational product 3 Participants switching from previous PCSK9 mab treatment (within 90 days prior to Index date)
Who the study is looking for
- Participants who are 18 years or older
- Participants with hypercholesterolemia having a diagnosis of ASCVD, ASCVD RE or HeFH
- Participants who are not at LDL-C goal as per their CV risk according to respective clinical guidelines
- Participants who per physician's criteria need to optimize their LLT
- Participants who provide written informed consent to participate in the study
- Participants who initiate inclisiran under conditions per local label and have LDL-C values available at baseline or within 3 months before treatment initiation.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (34)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Investigative Site Coordinator of this site? Confirm its status | Abu Dhabi | United Arab Emirates | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Al Ain City | United Arab Emirates | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Dubai | United Arab Emirates | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Feldkirch | Austria | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Graz | Austria | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Linz | Austria | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Sankt Veit im Pongau | Austria | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Vienna | Austria | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Basel | Switzerland | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Fribourg | Switzerland | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Geneva | Switzerland | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Lausanne | Switzerland | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Olten | Switzerland | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Sankt Gallen | Switzerland | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Zurich | Switzerland | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Shenzhen | China | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Belfast | United Kingdom | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Bromwich | United Kingdom | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Burton-on-Trent | United Kingdom | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | High Wycombe | United Kingdom | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Hull | United Kingdom | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Lancaster | United Kingdom | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Liverpool | United Kingdom | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Louth | United Kingdom | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Middlesex | United Kingdom | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Sunderland | United Kingdom | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Holon | Israel | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Petah Tikva | Israel | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Tel Aviv | Israel | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Kuala Lumpur | Malaysia | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Jeddah | Saudi Arabia | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Riyadh | Saudi Arabia | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Tabuk | Saudi Arabia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.